Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer Clinical Trial

Official title:

A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00613626
• Other study ID #: LUN06-113
• Status: Completed
• Phase: Phase 2
• Start date: January 2008
• Est. completion date: August 2015

Study information

• Verified date: February 2020
• Source: Hoosier Cancer Research Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.

Description:

OUTLINE: This is a multi-center study.

Arm A:

Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + Placebo oral daily given continuously for the duration of the study

Arm B:

Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + ZD6474 100mg oral daily given continuously for the duration of the study

For both arms, PE and toxicity evaluation prior to each cycle and disease assessment by imaging every 2 cycles. Patients with non-PD and acceptable toxicity will continue protocol therapy; patients with progressive disease or excessive toxicity will be taken off treatment. Cycles will be repeated every 21 days up to a total of 4 cycles.

ECOG Performance Status of 0 or 1

Life Expectancy: Not specified

Hematopoietic:

• Platelets > 100K/mm3

• Absolute neutrophil count (ANC) > 1.5K/mm3

Hepatic:

• Bilirubin < 1.5 x ULN

• Aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if judged by the investigator to be related to liver metastases

• Alkaline phosphatase < 2.5 x ULN or < 5 x ULN if judged by the investigator to be related to liver metastases

Renal:

• Serum creatinine < 1.5 x ULN or Calculated creatinine clearance of > 45 cc/min using the Cockcroft-Gault formula

Cardiovascular:

• No clinically significant cardiac event such as myocardial infarction; New York Heart Association (NYHA) classification of heart disease >2 (see SPM) within 3 months prior to registration for protocol therapy

• No presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.

• No history of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is permitted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological or cytological proof of chemotherapy-naïve, extensive, small cell lung cancer.

• Measurable disease according to RECIST and obtained by imaging within 28 days prior to being registered for protocol therapy.

• Written informed consent and HIPAA authorization for release of personal health information.

• Age 18 years or older at the time of consent.

• Potassium =4.0 mmol/L and <5.5mmol/L (supplementation is allowed).

• Calcium within normal range (supplementation is allowed).

• Magnesium within normal range (supplementation is allowed).

Exclusion Criteria:

• No prior EGFR inhibitor or antiangiogenic agent allowed.

• No prior hormonal therapy.

• No symptomatic brain metastasis.

• No clinically significant infections as judged by the treating investigator.

• No evidence of severe or uncontrolled other systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol.

• No previous history of QTc prolongation as a result of medication that required discontinuation of that medication.

• No congenital long QT syndrome or known 1st degree relative with unexplained sudden death under 40 years of age.

• No presence of left bundle branch block (LBBB.)

• No QTc with Bazett's correction that is unmeasurable, or =480 msec on screening ECG obtained within 7 days prior to registration for protocol therapy. If a subject has QTc =480 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be <480 msec in order for the subject to be eligible for the study.

• No concomitant (within 14 days prior to registration for and during protocol therapy) medication associated with Torsades de Pointes or cause QTc prolongation, is allowed. Medications that prolong QT, but are not strictly associated with Torsades, are allowed if medically necessary and will require increased ECG and electrolyte monitoring.

• No uncontrolled hypertension (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg).

• No currently active diarrhea that may affect the ability to absorb ZD6474.

• No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason < grade 7 prostate cancers, or other cancer for which the subject has been disease-free for at least 5 years.

• Major surgery must be completed greater than 28 days prior to registration for protocol therapy and healed surgical incision is required.

• No concomitant (within 14 days prior to registration for and during protocol therapy) medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of CYP3A4 function.

• Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.

• Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.

• Females must not be breastfeeding.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• Cisplatin
Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
• Etoposide
Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
• Placebo
Matched placebo oral daily
• ZD6474
ZD6474 100mg oral daily to be continued for the duration of the study.

Locations

Country	Name	City	State
United States	Cancer Care Center of Southern Indiana	Bloomington	Indiana
United States	Northwestern University Feinberg School of Medicine	Chicago	Illinois
United States	Oncology Hematology Associates of SW Indiana	Evansville	Indiana
United States	Fort Wayne Oncology & Hematology, Inc	Fort Wayne	Indiana
United States	Medical & Surgical Specialists, LLC	Galesburg	Illinois
United States	IN Onc/Hem Associates	Indianapolis	Indiana
United States	Indiana University Simon Cancer Center	Indianapolis	Indiana
United States	St. Vincent Hospital & Health Centers	Indianapolis	Indiana
United States	Horizon Oncology Researcg	Lafayette	Indiana
United States	IU Health Arnett Cancer Center	Lafayette	Indiana
United States	Hematology Oncology Associates S.J., P.A.	Mount Holly	New Jersey
United States	IU Health at Ball Memorial Hospital	Muncie	Indiana
United States	Monroe Medical Associates	Munster	Indiana
United States	Helen F. Graham Cancer Center	Newark	Delaware
United States	Methodist Cancer Center	Omaha	Nebraska
United States	Pennsylvania Oncology-Hematology Associates	Philadelphia	Pennsylvania
United States	Providence Portland Medical Center	Portland	Oregon
United States	Northern Indiana Cancer Research Consortium	South Bend	Indiana
United States	Providence Medical Group	Terre Haute	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
Hoosier Cancer Research Network	AstraZeneca

Country where clinical trial is conducted

United States, 

References & Publications (1)

Rachel E. Sanborn, Jyoti D. Patel, Gregory A. Masters, Nagesh Jayaram, Anthony W. Stephens, Michael J. Guarino, Jamal Ghazi Misleh, Corinne E. Williams, Jingwei Wu, Nasser H. Hanna. A randomized double-blind phase II trial of platinum (P) plus etoposide (

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Disease Progression - Median Time to Progression and Log-Rank Test	Kaplan-Meier analysis comparing arm A to arm B. Median time to progression and log-rank test. Safety lead-in participants are not included in this analysis per protocol.	24 months
Secondary	Percentage of Participants With Grade 3/4 Hematologic and Non-Hematologic Toxicities	Percentage of participants who experienced grade 3/4 hematologic and non-hematologic toxicities. Participants from Arm A were compared to subjects from Arm B + Safety Lead-In.	6 weeks (2 Cycles)
Secondary	Measure the Response Rate (CR + PR) in Each Arm	Response assessments completed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST Therasse et al., 2000). Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: >=30% decrease in the sum of the longest diameter of target lesions.	24 months
Secondary	Measure Disease Control Rate (CR + PR+ SD) in Each Arm	Response assessments completed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST Therasse et al., 2000). Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: >=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD) is defined as: neither a partial response or progressive disease ( >=20% increase in the sum of the longest diameter of the target lesions).	24 months
Secondary	Measure Overall Survival for Each Arm		24 months
Secondary	Assess VEGF Polymorphisms and Correlate Subject Response		24 months

External Links

•   Hoosier Oncology Group Home Page